Work

Tirzepatide Improved Markers of Islet Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared to Semaglutide in People with Type 2 Diabetes

Year: 2024

Type: article

Source: Metabolism

DOI: 10.1016/j.metabol.2024.155883

Authors: Katelyn Brown, Laura Fernandez Landó, Brandon Bergman, Melissa K. Thomas, Bing Liu, Clare Lee, Amanda M. Giebel

Institution: Eli Lilly (United States)

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W4399704093

FWCI:

Cites:

Cited by:

Related to: 10